Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

University of Toronto

$87,500.00

Development of a Novel Class of Anti-HIV-1 Inhibitors Targeting Viral RNA Processing

EF 2012-13

Résumé
The increasing cases of resistant HIV-1 to current drugs are an alarming concern. New tactics are necessary for continued success in combating HIV-1 infection. Previous studies established that viral growth can be affected by manipulating cellular host factors involved in viral RNA processing. We have advanced these studies by demonstrating that compounds can inhibit HIV-1 growth, establishing that targeting viral RNA processing with compounds/drugs is effective at impairing viral expansion. We have previously identified two FDA-approved drugs, chlorohexidine and digoxin, as novel inhibitors of this stage of the virus lifecycle. Unfortunately, chlorhexidine is not suitable for systemic use. However, doses of digoxin required to suppress HIV-1 replication (in clinical isolates) are suitable for human use, demonstrating the potential of RNA processing inhibitors in becoming novel ARTs. To expand on our approach, I searched and identified five more inhibitors within the digoxin family of drugs (cardiac glycosides, CGs) and six more splice modulators. Of these, three CGs are even more potent and closer to clinical doses in use than digoxin. In this proposal, I will (1) complete the characterization of lead compounds in our HIV-1 cell line. Next, I will (2) investigate the mechanisms by how these compounds influence host cells to specifically inhibit HIV-1 replication. Lastly, I will (3) confirm the effectiveness of our best inhibitors against viral replication using HIV-1 clinical isolates. In summary, this research will develop a novel class of antiretroviral drugs that alters HIV-1 RNA processing-a stage of the virus lifecycle not targeted by current antiretroviral therapies. Since these inhibitors target host processes and a subset are already in clinical use, they show great promise in becoming broad spectrum inhibitors of multiple HIV-1 strains, reducing chances of virus resistance, and allow rapid re-purposing into novel HIV-1 antiretroviral therapies.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
283951
Name
Wong Raymond
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Development of a Novel Class of Anti-HIV-1 Inhibitors Targeting Viral RNA Processing
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$87,500
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Antiretroviral Therapy; Elisa; Gene Expression; High Throughput Screening; Hiv-1; Immunofluorescence Microscopy; Mammalian Cell Culture; Qrt-Pcr; Rna Splicing; Western Blotting
Abstract
The increasing cases of resistant HIV-1 to current drugs are an alarming concern. New tactics are necessary for continued success in combating HIV-1 infection. Previous studies established that viral growth can be affected by manipulating cellular host factors involved in viral RNA processing. We have advanced these studies by demonstrating that compounds can inhibit HIV-1 growth, establishing that targeting viral RNA processing with compounds/drugs is effective at impairing viral expansion. We have previously identified two FDA-approved drugs, chlorohexidine and digoxin, as novel inhibitors of this stage of the virus lifecycle. Unfortunately, chlorhexidine is not suitable for systemic use. However, doses of digoxin required to suppress HIV-1 replication (in clinical isolates) are suitable for human use, demonstrating the potential of RNA processing inhibitors in becoming novel ARTs. To expand on our approach, I searched and identified five more inhibitors within the digoxin family of drugs (cardiac glycosides, CGs) and six more splice modulators. Of these, three CGs are even more potent and closer to clinical doses in use than digoxin. In this proposal, I will (1) complete the characterization of lead compounds in our HIV-1 cell line. Next, I will (2) investigate the mechanisms by how these compounds influence host cells to specifically inhibit HIV-1 replication. Lastly, I will (3) confirm the effectiveness of our best inhibitors against viral replication using HIV-1 clinical isolates. In summary, this research will develop a novel class of antiretroviral drugs that alters HIV-1 RNA processing-a stage of the virus lifecycle not targeted by current antiretroviral therapies. Since these inhibitors target host processes and a subset are already in clinical use, they show great promise in becoming broad spectrum inhibitors of multiple HIV-1 strains, reducing chances of virus resistance, and allow rapid re-purposing into novel HIV-1 antiretroviral therapies.
Competitiondate
201210
Approvedterm2
2 yrs 6 mths
Pinamesdelim
Wong, Raymond
Approvedterm
2 ans 6 mois
Cihrcontribution2
~ $87,500~ $0~